GoldenGolden
Advanced Search
Onconova Therapeutics

Onconova Therapeutics

A company dveloping small molecule drugs for the treatment of cancer

All edits

Edits on 17 Jun, 2021
Neelam Jhaveri
Neelam Jhaveri approved a suggestion from Golden's AI on 17 Jun, 2021
Edits made to:
Article (+5/-5 characters)
Article

Onconova’s novel, proprietary multi-kinase inhibitor ON 123300 is planned to begin a dose-escalation and expansion Phase 1 trial in the U.S. in 2Q21, and a dose-escalation and expansion Phase 1 trial is currently underway in ChinaChina. Its product candidate oral rigosertib, is currently in a dose-escalation and expansion Phase 1 investigator-initiated study, targeting patients with advanced KRAS+ lung adenocarcinoma in combination with nivolumab.

Erin Scherfner"prospector:332:163235"
Erin Scherfner edited on 16 Jun, 2021
Edits made to:
Infobox (+2 properties)
Infobox
Country
United States
Edits on 6 May, 2021
Neelam Jhaveri
Neelam Jhaveri approved a suggestion from Golden's AI on 6 May, 2021
Edits made to:
Article (+11/-11 characters)
Article

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on discovering and developing products for cancer patients. Its proprietary targeted anti-cancer agents are designed to disrupt specific cellular pathways that are important for cancer cellcancer cell proliferation.

Nureni Akanji
Nureni Akanji edited on 5 May, 2021
Edits made to:
Article (+1035 characters)
Article

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on discovering and developing products for cancer patients. Its proprietary targeted anti-cancer agents are designed to disrupt specific cellular pathways that are important for cancer cell proliferation.

Onconova’s novel, proprietary multi-kinase inhibitor ON 123300 is planned to begin a dose-escalation and expansion Phase 1 trial in the U.S. in 2Q21, and a dose-escalation and expansion Phase 1 trial is currently underway in China. Its product candidate oral rigosertib, is currently in a dose-escalation and expansion Phase 1 investigator-initiated study, targeting patients with advanced KRAS+ lung adenocarcinoma in combination with nivolumab.

...

The company is dedictated to delivering novel solutions to cancer patients who are in need. It seeks to develop products that enhance the outcome for cancer patients by addressing the disease, its recurrence, and the burden of side-effects that are associated with the current methods of treatment.

Edits on 20 Mar, 2021
Golden AI"adding inverse field"
Golden AI edited on 20 Mar, 2021
Edits made to:
Infobox (+1 properties)
Golden AI"adding inverse field"
Golden AI edited on 19 Mar, 2021
Edits made to:
Infobox (+1 properties)
Golden AI"adding inverse field"
Golden AI edited on 19 Mar, 2021
Edits made to:
Infobox (+1 properties)
Golden AI"adding inverse field"
Golden AI edited on 19 Mar, 2021
Edits made to:
Infobox (+1 properties)
Edits on 18 Mar, 2021
Golden AI"adding inverse field"
Golden AI edited on 18 Mar, 2021
Edits made to:
Infobox (+1 properties)
Edits on 18 Mar, 2021
Golden AI"adding inverse field"
Golden AI edited on 18 Mar, 2021
Edits made to:
Infobox (+1 properties)
Edits on 6 Mar, 2021
Golden AI"Auto-imported"
Golden AI edited on 6 Mar, 2021
Edits made to:
Infobox (+1 properties)
Infobox
D-U-N-S Number
066821492
Edits on 16 Feb, 2021
Golden AI"prospector:149:81431"
Golden AI edited on 16 Feb, 2021
Edits made to:
Infobox (+5 properties)
Infobox
Legal name
Onconova Therapeutics, Inc.
Industry
Edits on 24 Oct, 2020
Golden AI
Golden AI edited on 24 Oct, 2020
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 6 Oct, 2020
Golden AI"Funding autocalculation"
Golden AI edited on 6 Oct, 2020
Edits made to:
Infobox (+1 properties)
Infobox
Latest funding round date
August 14, 2012
Edits on 26 Mar, 2020
Golden AI"Funding autocalculation"
Golden AI edited on 26 Mar, 2020
Edits made to:
Infobox (+1 properties)
Infobox
Total funding amount (USD)
50,000,000
Edits on 12 Jun, 2019
Golden AI
Golden AI edited on 12 Jun, 2019
Edits made to:
Infobox (+1 properties)
Edits on 23 May, 2019
Golden AI
Golden AI edited on 23 May, 2019
Edits made to:
Infobox (+1 properties)
Infobox
Location
Edits on 29 Mar, 2019
Dawson Sewell"Approved suggestion from source: http://www.onconova.com"
Dawson Sewell approved a suggestion from Golden's AI on 29 Mar, 2019
Edits made to:
Infobox (+1 properties)
Edits on 26 Mar, 2019
Dawson Sewell"Approved suggestion from source: http://www.onconova.com"
Dawson Sewell approved a suggestion from Golden's AI on 26 Mar, 2019
Edits made to:
Infobox (+1 properties)
Edits on 20 Feb, 2019
Henry Ogolla
Henry Ogolla approved a suggestion from Golden's AI on 20 Feb, 2019
Edits made to:
Infobox (+6 properties)
Infobox
Stock exchange
Stock symbol
ONTX
Place of incorporation
Headquarters
CIK Number
1,130,598
SIC Code
2,834
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.